Dose-Escalation Study in Advanced Colon Cancer Patients
NCT ID: NCT00969046
Last Updated: 2020-12-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
60 participants
INTERVENTIONAL
2003-11-30
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bolus
20 min bolus infusion
EPO906 (patupilone)
CIV-1d
1 day continuous infusion
EPO906 (patupilone)
CIV-5d
5 day continuous infusion
EPO906 (patupilone)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EPO906 (patupilone)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥ 18 years
3. Life expectancy ≥ 12 weeks
4. WHO performance status of 0-1
5. Negative serum pregnancy test
6. Adequate hepatic or renal function and hematological parameters
Exclusion Criteria
2. Ileostomy or colonostomy
3. History of pelvic radiotherapy
4. Grade \> 1 diarrhea at baseline
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Royal London Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Hradec Králové, , Czechia
Novartis Investigative Site
Prague, , Czechia
Novartis Investigative Site
Saint-Herblain, , France
Novartis Investigative Site
Toulouse, , France
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Results for CEPO906A2117 can be found on the Novartis Clinical Trial Results Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CEPO906A2117
Identifier Type: -
Identifier Source: org_study_id